144 related articles for article (PubMed ID: 19780257)
1. Biobehavioral factors in chemotherapy-induced nausea and vomiting.
Roscoe JA; Morrow GR; Hickok JT; Mustian KM; Shelke AR
J Natl Compr Canc Netw; 2004 Sep; 2(5):501-8. PubMed ID: 19780257
[TBL] [Abstract][Full Text] [Related]
2. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Lorusso V; Karthaus M; Aapro M
Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.
Osoba D; Warr DG; Fitch MI; Nakashima L; Warren B
Can J Oncol; 1995 Sep; 5(3):381-400. PubMed ID: 8853513
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
6. Behavioral treatment of chemotherapy-induced nausea and vomiting.
Morrow GR; Hickok JT
Oncology (Williston Park); 1993 Dec; 7(12):83-9; discussion 93-4, 97. PubMed ID: 8292509
[TBL] [Abstract][Full Text] [Related]
7. Control of nausea and vomiting in chemotherapy patients. Four effective behavioral methods.
Redd WH
Postgrad Med; 1984 Apr; 75(5):105-7, 110-3. PubMed ID: 6143308
[No Abstract] [Full Text] [Related]
8. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
9. Persistent anticipatory nausea, vomiting, and anxiety in cured Hodgkin's disease patients after completion of chemotherapy.
Cella DF; Pratt A; Holland JC
Am J Psychiatry; 1986 May; 143(5):641-3. PubMed ID: 3963254
[TBL] [Abstract][Full Text] [Related]
10. Nausea and emesis: evidence for a biobehavioral perspective.
Morrow GR; Roscoe JA; Hickok JT; Andrews PR; Matteson S
Support Care Cancer; 2002 Mar; 10(2):96-105. PubMed ID: 11862499
[TBL] [Abstract][Full Text] [Related]
11. Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
du Bois A; Vach W; Cramer-Giraud U; Thomssen C; Glaubitz M; Fiola M
Anticancer Drugs; 1995 Oct; 6(5):645-51. PubMed ID: 8845474
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of behavioral intervention for reduction of nausea and vomiting in children and adolescents receiving chemotherapy.
Zeltzer L; LeBaron S; Zeltzer PM
J Clin Oncol; 1984 Jun; 2(6):683-90. PubMed ID: 6726307
[TBL] [Abstract][Full Text] [Related]
13. Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings.
Hickok JT; Roscoe JA; Morrow GR; Stern RM; Yang B; Flynn PJ; Hynes HE; Kirshner JJ; Rosenbluth RJ
Cancer; 1999 Jul; 86(1):64-71. PubMed ID: 10391565
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.
Takahashi T; Kumanomidou S; Takami S; Okada T; Adachi K; Jo Y; Ikejiri F; Onishi C; Kawakami K; Miyake T; Inoue M; Moriyama I; Suzuki R; Suzumiya J
Int J Hematol; 2016 Sep; 104(3):378-83. PubMed ID: 27312042
[TBL] [Abstract][Full Text] [Related]
16. Management of other non-cisplatin-induced emesis.
Schmoll HJ; Casper J
Oncology; 1996 Jun; 53 Suppl 1():51-5. PubMed ID: 8692552
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.
Salvo N; Doble B; Khan L; Amirthevasar G; Dennis K; Pasetka M; Deangelis C; Tsao M; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):408-17. PubMed ID: 21075553
[TBL] [Abstract][Full Text] [Related]
18. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
19. The pathophysiology of treatment-related nausea and vomiting in cancer patients: current models.
Shelke AR; Mustian KM; Morrow GR
Indian J Physiol Pharmacol; 2004 Jul; 48(3):256-68. PubMed ID: 15648398
[TBL] [Abstract][Full Text] [Related]
20. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy.
Morrow GR; Morrell C
N Engl J Med; 1982 Dec; 307(24):1476-80. PubMed ID: 6128673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
